
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD Inc has demonstrated strong growth in its Telehealth segment, with a year-over-year increase of 14% in active subscribers, reaching 310,818 by the end of the third quarter of 2025. The company reported total revenue of $60.2 million, reflecting a 12.7% year-over-year growth, with Telehealth revenue increasing by 17.4% to $47.3 million. Additionally, the gross margin expanded to 87%, indicating a favorable revenue mix which bodes well for the company’s overall profitability and potential for further growth.
Bears say
LifeMD Inc. faces significant challenges that contribute to a negative outlook for its stock, including lower than projected telehealth revenue growth and difficulties in patient acquisition and retention. The company reported third-quarter revenue of $60.2 million, a 13% year-over-year increase, but it fell short of consensus expectations and guidance, while adjusted EBITDA also did not meet forecasts. Additionally, revenue guidance for full-year 2025 has been reduced, now anticipated to be between $192 million and $193 million, highlighting concerns about the sustainability of its revenue growth amidst increased competition and operational adjustments.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares